At some point in your research career, you may find yourself transitioning from academia to industry or vice versa. To best ...

As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: ...

The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...

Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment ...

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

The initiative could tackle the first-mover disadvantage some CDMOs believe deters early customers, but leaders at companies ...

As biotechs faced investors at the J.P. Morgan Healthcare Conference this week, they emphasized agreement with the FDA on ...

Two more biopharma companies—the hair-growth specialist Veradermics and cancer-focused Eikon Therapeutics—have announced ...

Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting ...

Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...

Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of ...

After J.P. Morgan, biotech’s bold promises meet real-world challenges. In 2026, success starts with a CDMO partner who ...